<DOC>
	<DOCNO>NCT02859948</DOCNO>
	<brief_summary>Patients receive oral SKLB1028 28 day study side effect , tolerability best dose treat relapsed refractory acute myeloid leukemia With FLT3 Mutations .</brief_summary>
	<brief_title>A Study SKLB1028 Subjects With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>It open-label , dose escalation study design characterize safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) orally administer SKLB1028 single agent give daily 28 day . Cohorts 3 patient receive SKLB1028 dose limit toxicity note ( DLT ) . At point cohort expand 6 patient MTD determine . Patients experience DLT significant disease progression could continue receive SKLB1028 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Written informed consent must provide . Males females age ≥ 18 year ; Histopathologically document primary secondary AML , define WHO criterion , confirm pathology review treat institution , meet least one following : 1 . Refractory least 1 cycle induction chemotherapy , 2 . Relapsed least 1 cycle induction chemotherapy , 3 . Patient , accord clinical judgment Principal Investigator , candidate induction chemotherapy due age , comorbidity , factor ; Eastern Cooperative Oncology Group ( ECOG ) performance status 03 ; In absence rapidly progress disease , interval prior treatment time SKLB1028 administration least 2 week cytotoxic agent , least 5 halflives noncytotoxic agent ; Serum creatinine ≤1.5 × ULN ; Total serum bilirubin ≤ 1.5 × ULN unless consider due Gilbert 's syndrome leukemic organ involvement ; Serum AST ALT ≤ 3.0 × ULN unless consider due leukemic organ involvement ; Females childbearing potential sexually mature male must agree use medically accept method contraception throughout study ; Histologic diagnosis acute promyelocytic leukemia ; Clinically active central nervous system leukemia ; Persistent clinically significant toxicity prior chemotherapy Grade 2 high ; Bone marrow transplant within 100 day prior study ; Active , uncontrolled infection ; Major surgery within 4 week prior study ; Radiation therapy within 4 week prior study ; Left ventricular ejection fraction ≤1 × ULN , or﹤50 % . Clinically significant ECG QTc prolongation ( Male : &gt; 450ms , Female : &gt; 470ms ) .Significant cardiac disease . Human immunodeficiency virus positivity ; Active hepatitis B C active liver disease ; Women pregnant , lactate ; Medical condition , serious intercurrent illness , extenuate circumstance , judgment Principal Investigator , could jeopardize patient safety interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
</DOC>